寻找心力衰竭的理想药物与减少喷射率:一个叙事审查
Domingo Pascual-Figal1,2,3, Antoni Bayes-Genis4
1Cardiology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Frontiers in cardiovascular medicine
|September 24, 2024
概括
以指导方针为导向的心力衰竭治疗与减少喷射率 (HFrEF) 减少死亡率和住院治疗. 这些疗法还可以改善心脏重塑,功能以及住院患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 减少喷射率心力衰竭 (HFrEF) 管理旨在减少死亡率和住院治疗.
- 最佳的HFrEF治疗应解决可变性,并发病症,并提供超出心血管系统的器官保护.
研究的目的:
- 审查指导方针导向的HFrEF治疗对关键临床结果的已证明影响.
- 评估对心血管死亡率,HF住院,突然死亡,逆心脏改造,脏保护和住院患者的影响.
主要方法:
- 对符合预先确定的选择标准的出版物进行叙述性审查.
- 对氨酸- ангиотензин系统 (RAS) 抑制剂 (ACE-I,ARBs,ARNI),β-阻断剂 (BB),矿物质皮质体受体对抗剂 (MRA) 和SGLT2抑制剂 (SGLT2i) 的证据分析.
主要成果:
- 拉斯抑制剂,BB,MRA和SGLT2i可以降低死亡率和住院率.
- ARNI,BB和MRA显著降低了突然死亡的发生率.
- ARB,ARNI,BB和SGLT2i促进逆心脏重塑;ARB,ARNI,SGLT2i提供脏保护;ARNI和SGLT2i有利于住院患者.
结论:
- 在HFrEF中,指南导向医学疗法提供了广泛的好处,不仅仅是减少死亡率和住院治疗.
- 结合具有多种益处的药物,包括逆心脏改造和器官保护,是全面HFrEF管理的理想选择.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.